Latest news with #InspireMedical
Associated Press
10 hours ago
- Business
- Associated Press
Kaplan Fox Investigates Inspire Medical Systems, Inc. (INSP) After Stock Drops 32% on Reduced 2025 Outlook
NEW YORK, NY - August 18, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Inspire Medical Systems. ('Inspire' or the 'Company') (NYSE: INSP). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are an Inspire investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003. On August 4, 2025, after markets closed, Inspire issued a press release announcing its second quarter financial results and updating its 2025 outlook. Inspire reduced both its 2025 full-year revenue outlook and diluted net income per share. The Company attributed the reductions in 2025 guidance to the 'slower than expected' U.S. commercial launch of the next generation Inspire V neurostimulation system. Following this news, the price of Inspire stock fell $42.04 per share, or 32.35%, to close at $87.91 per share on August 5, 2025. WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this investigation, please contact: CONTACT: Pamela A. Mayer KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (646) 315-9003 [email protected] Laurence D. King KAPLAN FOX & KILSHEIMER LLP 1999 Harrison Street, Suite 1560 Oakland, California 94612 (415) 772-4704 [email protected] Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
Yahoo
05-08-2025
- Business
- Yahoo
INSP Stock Plunges Despite Q2 Earnings Beat, Gross Margin Contracts
Inspire Medical Systems, Inc. INSP delivered an earnings per share (EPS) of 45 cents in second-quarter 2025, up 40.6% year over year. The figure topped the Zacks Consensus Estimate by 104.6%. INSP's Revenues in Detail Inspire Medical registered revenues of $217.1 million in the second quarter, up 10.8% year over year. The figure beat the Zacks Consensus Estimate by 0.9%. Per management, the overall revenue growth was primarily driven by increased market penetration and increased physician and patient awareness of the Inspire system. However, this was partially offset by ENT surgeon capacity constraints and some U.S. patients and physicians delaying Inspire therapy until Inspire V is available at their location or while they trial GLP-1 medications. Shares of this company lost nearly 24.9% in today's pre-market trading. Inspire Medical's Segment Details Inspire Medical's operations consist of two geographic regions — the United States and All other countries. In the quarter under review, U.S. revenues of $207.2 million reflected an increase of 10.3% from the year-ago quarter on a reported basis. As of June 30, 2025, Inspire Medical had 348 U.S. sales territories and 259 field clinical representatives compared with 335 and 230, respectively, as of Dec. 31, 2024. Revenues from All other countries totaled $9.9 million, up 23% year over year on a reported basis. Inspire Medical Systems, Inc. Price, Consensus and EPS Surprise Inspire Medical Systems, Inc. price-consensus-eps-surprise-chart | Inspire Medical Systems, Inc. Quote INSP's Margin Analysis In the second quarter, Inspire Medical's gross profit increased 9.9% year over year to $182.4 million. However, the gross margin contracted 74 basis points (bps) to 84%. Selling, general and administrative expenses jumped 20.8% year over year to $159.5 million. Research and development expenses decreased 9.2% year over year to $26.2 million. Operating expenses of $185.7 million increased 15.4% year over year. Operating loss totaled $3.3 million against the prior-year quarter's operating profit of $5.1 million. Inspire Medical's Financial Position Inspire Medical exited second-quarter 2025 with cash and cash equivalents and short-term investments of $300.9 million compared with $369.2 million at the first-quarter end. Cumulative net cash used in operating activities at the end of second-quarter 2025 was $4 million, against net cash provided by operating activities of $8.8 million a year ago. INSP's Outlook Inspire Medical has lowered its revenue and EPS outlook for 2025. The company now projects revenues in the range of $900 million-$910 million (representing growth of 12-13% from 2024 levels), lowered from the prior outlook of $940 million-$955 million (representing growth of 17-19% from 2024 levels). The Zacks Consensus Estimate is pegged at $949.1 million. The company now expects its EPS for 2025 to be between 40 cents and 50 cents, lowered from the prior outlook of $2.20-$2.30. The Zacks Consensus Estimate is pegged at $2.26. Our Take on Inspire Medical Inspire Medical exited the second quarter of 2025 with better-than-expected results. The robust improvement of the top and bottom lines was impressive. Strength in year-over-year geographical revenues was promising. The increased market penetration and increased physician and patient awareness of the Inspire system during the reported quarter were encouraging. However, the gross margin contracted due to rising product costs. This does not bode well for the stock. Also, management's confirmation about the slower-than-expected progress of the U.S. commercial launch of Inspire V is worrying. Per management, this has resulted in the pushing forward of the timeline to complete the full transition to Inspire V, which will impact financial results for the year. INSP's Zacks Rank and Key Picks Inspire Medical currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader medical space that have announced quarterly results are GE HealthCare Technologies Inc. GEHC, West Pharmaceutical Services, Inc. WST and Boston Scientific Corporation BSX. GE HealthCare, sporting a Zacks Rank #1 (Strong Buy), reported second-quarter 2025 adjusted EPS of $1.06, beating the Zacks Consensus Estimate by 16.5%. Revenues of $5.01 billion outpaced the consensus mark by 0.7%. You can see the complete list of today's Zacks #1 Rank stocks here. GE HealthCare has a long-term estimated growth rate of 5.8%. GEHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.5%. West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, beating the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1. West Pharmaceutical has a long-term estimated growth rate of 8.4%. WST's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%. Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2 (Buy). Boston Scientific has a long-term estimated growth rate of 14%. BSX's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report West Pharmaceutical Services, Inc. (WST) : Free Stock Analysis Report Inspire Medical Systems, Inc. (INSP) : Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
18-05-2025
- Business
- Bloomberg
Inspire Medical CEO on Improving Patient Outcomes
Tim Herbert, Founder, Chairman, President and CEO of publicly traded Inspire Medical Systems, discusses the company's breakthrough technology that helps people suffering from obstructive sleep apnea, as well as the company's strong quarterly earnings amid headwinds facing the broader health care industry. Tim speaks with Tim Stenovec and Emily Graffeo on Bloomberg Businessweek Daily. (Source: Bloomberg)
Associated Press
17-02-2025
- Business
- Associated Press
SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation of Inspire Medical Systems, Inc. (NYSE: INSP) and Encourages Long-Term Inspire Investors to Contact the Firm
Kaskela Law LLC announces that it is investigating Inspire Medical Systems, Inc. (NYSE: INSP) ('Inspire Medical') on behalf of the company's long-term shareholders. Recently a securities fraud complaint was filed against Inspire Medical on behalf of certain investors who purchased shares of the company's stock between May 3, 2023 and November 7, 2023. According to the complaint, during that time period Inspire Medical and certain of the company's senior executives made a series of materially false and/or misleading statements about the company's 'Acceleration Program,' which was reportedly designed to facilitate customers' receiving prior authorizations from doctors for Inspire Medical's sleep apnea products ('Inspire therapy') by acting as a liaison between patients and their doctors. As detailed in the complaint, on November 7, 2023, Inspire Medical announced disappointing earnings results for the third quarter of 2023 – its first reported revenue miss since becoming a public company in 2018. Therein, the company disclosed that it had started to 'track' problems with the Acceleration Program in the second quarter of 2023, including a decrease in the number of prior authorization submissions for Inspire therapy, and 'recogniz[ed] this trend early in the third quarter' ( i.e., as early as July 1, 2023). Following this news, shares of Inspire Medical's stock fell $31.79 per share, or nearly 20% in value, from a closing price of $161.74 per share on November 7, 2023 to a closing price of $129.65 per share on November 8, 2023. The investigation seeks to determine whether the members of Inspire Medical's board of directors violated the securities laws and/or breached their fiduciary duties in connection with the above alleged misconduct. Inspire Medical shareholders who purchased or acquired their currently held INSP shares prior to May 3, 2023 are encouraged to contact Kaskela Law LLC shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750 for additional information about this investigation and their legal rights and options. Alternatively, investors may submit their information to the firm by clicking on the following link (or if necessary, by copying and pasting the link into your browser): KASKELA LAW LLC D. Seamus Kaskela, Esq. Adrienne Bell, Esq. 18 Campus Blvd., Suite 100 Newtown Square, PA 19073 (888) 715 – 1740 (484) 229 – 0750
